Valuation : Freenome, Inc.

Market Cap 1.59B 1.37B 1.3B 1.18B 2.2B 152B 2.22B 15.39B 5.92B 77.16B 5.97B 5.84B 244B P/E 2026 *
-7.29x
P/E 2027 * -6.43x
Enterprise Value 1.59B 1.37B 1.3B 1.18B 2.2B 152B 2.22B 15.39B 5.92B 77.16B 5.97B 5.84B 244B EV / Sales 2026 *
15.5x
EV / Sales 2027 * 14x
Free-Float
74.05%
Yield 2026 *
-
Yield 2027 * -
1 day-6.10%
1 week-12.49%
1 month+27.28%
3 months+31.58%
6 months+28.27%
Current year+13.51%
1 week 14.37
Extreme 14.37
16.74
1 month 11.4
Extreme 11.4
17.18
Current year 9.95
Extreme 9.95
17.18
1 year 9.95
Extreme 9.95
17.18
3 years 9.95
Extreme 9.95
17.18
5 years 9.95
Extreme 9.95
17.18
10 years 9.95
Extreme 9.95
17.18
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Tax

Chief Executive Officer

-71,920 0.0669%
20/7/26 Other

Chief Executive Officer

835,791 0.3889%
20/7/26 Conversion -30,000 1.3913%
Change 5-day change 1-year change 3-year change Capi.($)
-6.10%-12.49%+40.19% - 1.59B
-0.12%-1.51%+94.85%+303.33% 3.87B
+5.65%-1.15%+261.34%+44.54% 3.69B
-2.76%-8.51%+32.61%+65.60% 3.38B
+0.48%+0.80%+277.04%+515.18% 2.59B
-1.24%-4.30%-29.60%-31.68% 2.08B
+0.16%0.00%+21.81%+41.80% 1.07B
-2.97%-11.40%+151.15%-39.70% 1B
-1.13%-0.83%+7.74%+53.60% 621M
-2.60%-3.97%-35.85%-12.88% 518M
Average -1.06%-4.71%+82.13%+104.42% 2.04B
Weighted average by Cap. -0.24%-4.31%+113.80%+151.95%

Financials

2026 *2027 *
Net sales 102M 88.32M 83.58M 75.76M 142M 9.78B 143M 992M 381M 4.97B 385M 376M 15.73B 114M 98.17M 92.9M 84.21M 158M 10.88B 159M 1.1B 424M 5.53B 428M 418M 17.48B
Net income -175M -151M -143M -130M -243M -16.73B -244M -1.7B -652M -8.5B -658M -643M -26.89B -246M -212M -201M -182M -341M -23.48B -343M -2.38B -915M -11.93B -923M -903M -37.74B
Net Debt - -
Logo Freenome, Inc.
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.
Employees
378
Date Price Change Volume
11/09/26 US$14.37 -2.84% 535,433
10/09/26 US$14.79 -6.10% 744,543
09/09/26 US$15.75 -1.50% 401,073
08/09/26 US$15.99 -1.96% 541,627
04/09/26 US$16.31 -3.49% 622,008
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.37USD
Average target price
18.00USD
Spread / Average Target
+25.26%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FRNM Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!